Radiopharm Theranostics Posts Solid Cash Runway and Positive Interim Data for Lead Brain Metastases Imaging Agent

Radiopharm Theranostics Limited ( (AU:RAD) ) has issued an announcement.

Radiopharm Theranostics reported its half-year financial results to 31 December 2025 alongside business updates, highlighting strong clinical progress across its oncology radiopharmaceutical pipeline and a solid cash position of approximately $34.52 million, which is expected to fund operations into 2027 through key clinical and regulatory milestones. Interim Phase 2b data for its lead imaging candidate RAD 101 in patients with recurrent brain metastases showed 92% MRI concordance, reinforcing earlier findings and supporting plans for a potential Phase 3 registrational study if results are confirmed, while additional Phase 1 data for therapeutic candidates RAD 202 and RAD 204 in advanced solid tumors are anticipated in mid-2026, underscoring the company’s focus on advancing multiple programs and enhancing its competitive positioning in radiotheranostics.

The most recent analyst rating on (AU:RAD) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.

More about Radiopharm Theranostics Limited

Radiopharm Theranostics Limited is a clinical-stage biopharmaceutical company developing innovative oncology radiopharmaceuticals, with a focus on diagnostic and therapeutic agents for solid tumors and other cancers with high unmet medical need. Listed on both the ASX and Nasdaq, the company is advancing a pipeline of radiotherapeutic and imaging candidates, targeting indications such as brain metastases, and is positioning itself as a specialist player in the growing radiotheranostics segment of the oncology market.

Average Trading Volume: 10,484,994

Technical Sentiment Signal: Sell

Current Market Cap: A$81.52M

For detailed information about RAD stock, go to TipRanks’ Stock Analysis page.